Stockreport

Is Erasca (ERAS) Quietly Reframing Its RAS Strategy With Tango's Dual-Target Trial Collaboration? [Yahoo! Finance]

Erasca, Inc.  (ERAS) 
PDF glue ERAS-0015 with Tango's PRMT5 inhibitor vopimetostat in MTAP-deleted pancreatic and RAS-mutant non-small cell lung cancer. The combination seeks to exploit the dep [Read more]